Gastroenterology

Shortened Stelara dose interval may improve activity in Crohn’s disease




Clinical and biological indices of disease activity improved in patients with Crohn’s disease when researchers shortened the Stelara 90 mg dose from every 8 weeks to every 4 weeks.
“Little is known about the effects of shortening the dosing interval for patients with Crohn’s disease who do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks,” Jacob E. Ollech, MD, of the Inflammatory Bowel Disease Center at the University of Chicago Medicine, told Healio Gastroenterology and Liver Disease. “In our study, we reported that shortening the ustekinumab 90

Source link





Related posts

Common polymorphism responsible for HCV genotype 3 resistance to Sovaldi

Newsemia

Reply to 19-00977

Newsemia

Degree and site of chromosomal instability define its oncogenic potential

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy